Methotrexate Drugs Market, by Treatment Type (Psoriasis, Rheumatoid Arthritis, Cancer), by Route of Administration (Oral, Injection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, La

Methotrexate Drugs Market, by Treatment Type (Psoriasis, Rheumatoid Arthritis, Cancer), by Route of Administration (Oral, Injection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Methotrexate is a type of disease-modifying anti-rheumatic drug (DMARD). It is used to reduce the activity of the immune system for people who have certain conditions. The immune system normally protects the body from infections by causing inflammation to fight them. Inflammation can cause swelling, heat, redness and pain. Methotrexate is available in tablet, liquid or injection form. Methotrexate tablets come in two strengths: 2.5 mg and 10 mg. Methotrexate interferes with the growth of certain cells of the body, especially cells that reproduce quickly, such as cancer cells, bone marrow cells, and skin cells.

Market Dynamics

Key players in market are involved in research and development activities to develop Methotrexate drugs which is expected to drive the growth of global methotrexate drugs market over the forecast period. For instance, in June 2019, Pfizer Inc., announced positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA). Patients who achieved low disease activity (LDA) with XELJANZ (tofacitinib) extended release (XR) 11 mg once daily (QD) plus methotrexate (MTX) after a 24-week open-label run-in period, were randomized to evaluate the efficacy and safety of XELJANZ XR 11 mg QD as monotherapy after MTX withdrawal compared with XELJANZ XR with continued MTX.

Factors such as awareness initiatives by organizations, increasing prevalence of Arthritis, and product launches are driving the global methotrexate drugs market growth. For instance, in May 2018, Hikma Pharmaceuticals PLC., announced that it is wholly owned U.S. subsidiary West-Ward Pharmaceuticals Corp., has launched Methotrexate for Injection, USP in a 1g preservative-free presentation and Methotrexate Injection, USP 50mg/2mL, 2 mL vials. Such initiatives by market players are expected to boost the global methotrexate drugs market growth over the forecast period. Moreover, pipeline for Arthtitis, cancers has several potential medications, which is expected to drive global methotrexate drugs market growth.

Key features of the study:

• This report provides an in-depth analysis of the global methotrexate drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global methotrexate drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include LEO Pharma A/S, Bristol Myers Squibb, Nordic Pharma, Eli Lilly and Company, Horizon Therapeutics plc., Cumberland Pharmaceuticals Inc., Azurity Pharmaceuticals, Inc., Pfizer Inc., Hikma Pharmaceuticals PLC., and Onco Therapies Limited (Strides Arcolab Limited).
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global methotrexate drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global methotrexate drugs market.

Detailed Segmentation:

• Global Methotrexate Drugs Market, By Treatment Type:
• Psoriasis
• Rheumatoid Arthritis
• Cancer
• Global Methotrexate Drugs Market, By Route of Administration:
• Oral
• Injection
• Global Methotrexate Drugs Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Methotrexate Drugs Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• LEO Pharma A/S*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Bristol Myers Squibb
• Nordic Pharma
• Eli Lilly and Company
• Horizon Therapeutics plc.
• Cumberland Pharmaceuticals Inc.
• Azurity Pharmaceuticals, Inc.
• Pfizer Inc.
• Hikma Pharmaceuticals PLC.
• Onco Therapies Limited (Strides Arcolab Limited)

“*” marked represents similar segmentation in other categories in the respective section.